🇺🇸 FDA
Pipeline program

ifezuntirgene inilparvovec, ifezuntirgene inilparvovec

CT-AMT-130-02

Phase 2 small_molecule active

Quick answer

ifezuntirgene inilparvovec, ifezuntirgene inilparvovec for Huntington’s Disease is a Phase 2 program (small_molecule) at uniQure biopharma B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
uniQure biopharma B.V.
Indication
Huntington’s Disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials